Study on ovarian leiomyosarcoma outcomes
Part of Cancer clinical trials.
This study looks at the medical care and results for people diagnosed with a rare type of ovarian cancer called primary ovarian leiomyosarcoma (POLMS). It aims to learn more about the disease and how it's managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary ovarian leiomyosarcoma
- You are between 18 and 99 years old
- Your diagnosis and treatment information is available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the medical details and outcomes of people with breast sarcoma. It may help doctors better understand what treatments and factors are linked to different results over time.
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
This study collects information and archived tumor samples from people with undifferentiated round cell sarcoma to better understand the disease. It may help future diagnoses and treatments by linking lab findings in tumor tissue to clinical outcomes.
This is an observational study for people diagnosed with epithelioid sarcoma, focused on how patients are followed over time. It does not appear to test a new treatment, but it can help doctors better understand the disease and follow-up needs.
This trial looks at lab markers (biomarkers) in tumor samples from people with leiomyosarcoma that has spread or can’t be fully removed. It also enrolls people who are receiving certain first-line chemotherapy, and your results may help guide future treatment decisions.
This trial uses your tumor's lab-grown organoids to find the most effective personalized treatment for advanced leiomyosarcoma. It aims to match you with a drug that targets your specific cancer.
Hear when a new Primary Ovarian Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.